Authors: Zack, M. D.; Melton, M. A.¹; Stock, J. L.¹; Storer, C. E.¹; Barve, R. A.¹; Minnerly, J. C.¹; Weiss, D. J.¹; Stejskal, J. A.¹; Tortorella, M. D.¹; Turk, J. R.²; Shevlin, K. M.¹; Malfait, A.-M.³

Source: Clinical & Experimental Immunology, Volume 158, Number 2, November 2009 , pp. 246-256(11)

Publisher: Wiley-Blackwell

Abstract:

Summary

A disintegrin and metalloproteinase 8 (ADAM8), a catalytically active member of the ADAMs family of enzymes, is expressed primarily on immune cells and thus probably involved in inflammatory responses. ADAM8 is also produced by chondrocytes, and recombinant ADAM8 can induce cartilage catabolism. We therefore decided to test the role of ADAM8 in autoimmune inflammatory arthritis using transgenic mice expressing catalytically inactive ADAM8. Transgenic DBA/1J mice expressing an inactivating point mutation in the ADAM8 gene to change Glu330 to Gln330 (ADAM8^EQ) were generated to evaluate the proteolytic function of ADAM8 in an lipopolysaccharide-synchronized collagen-induced arthritis (LPS-CIA) model of autoimmune arthritis. The systemic inflammatory reaction to LPS was also evaluated in these mice. Expression profiling of paw joints from wild-type mice revealed that ADAM8 mRNA levels increased at the onset of clinical arthritis and correlated well with cellular macrophage markers. When subjected to LPS-CIA, ADAM8^EQ mice demonstrated decreased incidence and severity of clinical arthritis compared to wild-type mice. Histological examination of paw joints from ADAM8^EQ mice confirmed marked attenuation of synovial inflammation, cartilage degradation and bone resorption when compared to wild-type mice. However, transgenic mice and wild-type mice responded similarly to LPS-induced systemic inflammation with regard to mortality, organ weights, neutrophil sequestration and serum cytokine/chemokine production. We conclude that ADAM8 proteolytic activity plays a key role in the development of experimental arthritis and may thus be an attractive target for the treatment of arthritic disorders while minimizing risk of immunocompromise.

Keywords: endotoxin shock; inflammation; rheumatoid arthritis; transgenic mice

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2249.2009.04009.x

Affiliations: 1: Pfizer Global Research and Development, Chesterfield, MO, 2: Amgen, Thousand Oaks, CA, and 3: Rush University Medical Center, Chicago, IL, USA

Publication date: 2009-11-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Microbiology ,  Allergy & Immunology
• By this author: Zack, M. D. ;  Melton, M. A. ;  Stock, J. L. ;  Storer, C. E. ;  Barve, R. A. ;  Minnerly, J. C. ;  Weiss, D. J. ;  Stejskal, J. A. ;  Tortorella, M. D. ;  Turk, J. R. ;  Shevlin, K. M. ;  Malfait, A.-M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers